From a ‘cute’ industry to the next wave of medicinal evolution: an interview with Miguel Forte
How can the field of cell and gene therapy navigate not only its own challenges of manufacturability, investment and maturity of the system, but also the challenges of society beyond science? We speak to Miguel Forte, CEO of Bone Therapeutics (Belgium) at International Society of Cellular Therapy 2022. Miguel comments on the importance of analyzing the field as a whole as it expands, as well as its place in the wider context of the world.
Miguel has over 20 years professional activity in clinical, academic and pharmaceutical industry environments, was previously CEO of Zelluna Immunotherapy (Norway), Vice-President Global Medical Affairs Inflammation at UCB (UK), Chief Medical Officer (CMO) at TxCell (now a subsidiary of Sangamo Therapeutics, France) and held a senior position at the European Medicines Agency (EMA). Dr Forte graduated in Medicine from the University of Lisbon (Portugal), specializing in infectious diseases. He then obtained a PhD in Immunology at the University of Birmingham (UK). He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, UK and Associate Professor in Health Sciences and Pharmacy at the University of Lisbon. He is currently serving as CEO of Bone Therapeutics and President Elect of the International Society of Cellular Therapy (ISCT).
Sarah Rehman
Sarah is the editor of RegMedNet and author of this article. She ensures that the site is up-to-date with the latest news and views in the field of regenerative medicine, from breakthrough therapies to industry collaborations. With a background in both Zoology and Ecology, she has a particular interest in the environmental impact of the industry and the innovations that could move us towards a sustainable future.